The global orphan drug market size was USD 154.20 Billion in 2022 and is expected to register a rapid revenue CAGR of 12.3 % ...

With orphan drugs typically being high value, the potential risk of stock losses should be a top concern for biotechs looking ...

The European orphan drug market is growing and is already comparable in size and scope to the US market. The European Union ...

EN001, ENCell’s therapy under development for the treatment of Charcot-Marie-Tooth (CMT) disease, has been granted Orphan ...

The FDA granted orphan drug status to rhenium-186 obisbemeda for treating leptomeningeal metastases in lung cancer.

HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing ...

PTC Therapeutics could boost revenue with vatiquinone for Friedreich's ataxia. Find out why PTCT stock is poised for growth ...

ENCell’s investigational drug EN001 has been granted Orphan Drug Designation by the FDA for the treatment of ...

While the IRA architects were building their anti-innovation government drug pricing plan, they also included a provision to ...

Detailed price information for Diagnamed Holdings Corp. (DMED-CN) from The Globe and Mail including charting and trades.

Plus Therapeutics (PSTV) soars with FDA's Orphan Drug Designation for Rhenium Obisbemeda, targeting rare leptomeningeal metastases.

Tucatinib inhibits the tyrosine kinase enzyme of the HER-2 gene. Mutations of tyrosine kinase in the HER-2 gene lead to ...